Cancel
Mindstate Design Labs
See Linkedin
Mindstate Design Labs Employees
15 people indexed:
-
xz62ubv@88x143rpq.25q2b7 Sign up to see email
-
c8zrwjf@ql84klcru.k67048 Sign up to see email
-
58fxj@8qk63y35k.93qj4o Sign up to see email
-
wfh743@7qk0phx5j.pojzu7 Sign up to see email
-
v50z@oyy0u48x7.858vpp Sign up to see email
-
hkkwyu933@6x3vvbw05.621yqf Sign up to see email
-
Jessica Smith Beaver
Head of Regulatory Affairs
-
Jianhong Wang
Head of DPMK
-
5h71w@9prw1xxzu.0xvqkp Sign up to see email
-
bwp@hqyo77v5w.h4uzj4 Sign up to see email
-
12w0@cr5qh1z0j.ryw5z5 Sign up to see email
-
501h0@x8vp7hc1z.zklouh Sign up to see email
-
Thomas Ray
Scientific Co-Founder
-
Tilmann Brotz
Head of Preclinical Development
-
r46@zzx77qz7v.jp9hyw Sign up to see email
Mindstate Design Labs Company Information
Mindstate Design Labs, previously known as Kykeon Biotechnologies Inc. and Kykeon Biotechnologies, is a healthcare company based in San Francisco, CA, and Pittsburgh, PA, USA. With a team of seven, the company operates within the sub-industry of drug discovery and delivery, focusing on developing the next generation of psychedelic therapeutics for mental health indications. Mindstate Design Labs employs artificial intelligence and machine learning to design novel altered states of consciousness, integrating machine learning, human experiential data, and molecular pharmacology. As part of the Y Combinator’s S21 batch, the company is recognized as an early-stage entity in the mental health tech and biotech sectors. Their innovative approach includes the Osmanthus platform, which targets discovery and phenotypic screening for altered conscious states. Their pipeline features a combination of psychedelic ‘primer’ compounds and non-psychedelic ‘probe’ compounds, with six probe candidates identified that show unique therapeutic potential when used with the lead primer.
Report inaccurate information
Report inaccurate information
